CHCatherine C. Hedrick

Catherine C. Hedrick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine C. Hedrick has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • David T. Bolick

    Cardiovascular Research Center, University of Charlottesville, Charlottesville, Virginia 22908, USA

    6 shared publications
  • Suseela Srinivasan

    From the Cardiovascular Research Center (J.P.M., M.H.N., A.J.W., S.S., M.D.S., C.A.M., C.C.H.), Department of Pharmacology (J.P.M., M.H.N., A.J.W., C.C.H.), and Department of Internal Medicine (C.R.A., C.A.M., C.C.H.), University of Virginia, Charlottesville

    5 shared publications
  • Marcus D. Skaflen

    From the Cardiovascular Research Center (D.T.B., M.D.S., C.C.H.), Department of Pharmacology (L.E.J., C.C.H.), Department of Microbiology (K.S.R.), Department of Molecular Physiology and Biological Physics (C.C.H.), University of Charlottesville, Charlottesville, Virginia and Cardiovascular Research Center (D.H., A.D.), University of Kentucky; and Department of Physiology (S.-C.K.), Kwandong University College of Medicine, South Korea

    3 shared publications
  • Melissa E. Hatley

    From the Cardiovascular Research Center (D.T.B., A.W., S.S., M.E.H., M.A.S., C.C.H.), and the Departments of Pharmacology (C.C.H.) and Microbiology (A.W.O., M.A.S.), University of Virginia, Charlottesville

    3 shared publications
  • Angela Whetzel

    From the Cardiovascular Research Center (D.T.B., A.W., S.S., M.E.H., M.A.S., C.C.H.), and the Departments of Pharmacology (C.C.H.) and Microbiology (A.W.O., M.A.S.), University of Virginia, Charlottesville

    2 shared publications
  • Jerry L. Nadler

    ¶Department of Diabetes, Beckman Research Institute, City of Hope National Medical Center, Duarte, California 91010 and the §Department of Microbiology and the ‡Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia 22908

    2 shared publications

Latest Publications

  • G2A Deficiency in Mice Promotes Macrophage Activation and Atherosclerosis

    by David T. Bolick, Marcus D. Skaflen, Laura E. Johnson, Seong-Chun Kwon, Deborah Howatt, Alan Daugherty, Kodi S. Ravichandran, Catherine C. Hedrick

    G2A is a stress-inducible G protein–coupled receptor that is expressed on several cell types within atherosclerotic lesions. We demonstrated previously that G2A deficiency in mice increased aortic monocyte recruitment and increased monocyte:endothelial interactions. To investigate the impact of G2A deficiency in macrophages, we isolated peritoneal macrophages from G2A +/+ ApoE −/− and G2A −/− ApoE −/− mice. G2A −/− ApoE −/− macrophages had significantly lower apoptosis than control macrophages. The prosurvival genes BCL-2, BCL-xL, and cFLIP were increased in G2A −/− ApoE −/− macrophages. Macrophages from G2A −/− ApoE −/− mice also had increased proinflammatory status that was indicative of a M1 macrophage phenotype. This was indicated by significantly increased nuclear translocation of nuclear factor κB, as well as production of interleukin-12p40, tumor necrosis factor α, and interleukin-6, and reduced expression of arginase-I. Moreover, G2A −/− ApoE −/− macrophages had reduced ability to engulf apoptotic cells in vitro. We examined atherosclerosis in mice fed a Western diet for 10 weeks and found that G2A deficiency increased lesion size in the aortic root by 50%. Plasma lipid levels were not changed in G2A −/− ApoE −/− mice. However, we found that absence of G2A increased the number of aortic macrophages and attenuated apoptosis in this cell type. Moreover, bone marrow transplantation studies indicated that deficiency of G2A in marrow-derived cells significantly contributed to atherosclerosis development. In the absence of G2A, increased macrophage activation and decreased apoptosis is associated with accumulation of macrophages in the aorta and increased atherosclerosis.


  • Open Access

    The G protein–coupled receptor G2A

    by Laura E. Johnson, Marc S. Elias, David T. Bolick, Marcus D. Skaflen, Richard M. Green, Catherine C. Hedrick

    The G2A receptor is a member of the ovarian cancer G protein–coupled receptor 1 family of stress-inducible G protein–coupled receptors. In this study, we examined the hepatobiliary effects of loss of function of G2A in mice fed either a chow or lithogenic diet. G2A-deficient (G2A−/−) mice fed chow had a 25% reduction in biliary phosphatidylcholine content, reduced hepatic gene expression of the phosphatidylcholine transporter adenosine triphosphate–binding cassette B4, and an 8-fold increase in expression of the nuclear receptor liver X receptor (LXR). Despite the increased expression of LXR, transcription of several LXR target genes was reduced. G2A−/− mice fed a lithogenic diet had rapid gallstone formation, an increased cholesterol saturation index, a 2.5-fold increase in farnesoid X receptor expression, a 5-fold increase in LXR expression, and a 90% reduction in cholesterol 7α-hydroxylase expression in comparison with wild-type mice. There were no changes in gallbladder volume. Conclusion: These data demonstrate that the G2A receptor is important for hepatobiliary bile salt, cholesterol, and phospholipid homeostasis and for the pathogenesis of cholesterol gallstone formation. (HEPATOLOGY 2008;48:1138–1148.)


  • Reduced Expression of ATP-Binding Cassette Transporter G1 Increases Cholesterol Accumulation in Macrophages of Patients With Type 2 Diabetes Mellitus

    by Jeremy P. Mauldin, Melissa H. Nagelin, Allison J. Wojcik, Suseela Srinivasan, Marcus D. Skaflen, Carlos R. Ayers, Coleen A. McNamara, Catherine C. Hedrick

    Background—Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis. A pivotal event in the development of atherosclerosis is macrophage foam cell formation. The ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 regulate macrophage cholesterol efflux and hence play a vital role in macrophage foam cell formation. We have previously found that chronic elevated glucose reduces ABCG1 expression. In the present study, we examined whether patients with type 2 diabetes mellitus had decreased ABCG1 and/or ABCA1, impaired cholesterol efflux, and increased macrophage foam cell formation.Methods and Results—Blood was collected from patients with and without type 2 diabetes mellitus. Peripheral blood monocytes were differentiated into macrophages, and cholesterol efflux assays, immunoblots, histological analysis, and intracellular cholesteryl ester measurements were performed. Macrophages from patients with type 2 diabetes mellitus had a 30% reduction in cholesterol efflux with a corresponding 60% increase in cholesterol accumulation relative to control subjects. ABCG1 was present in macrophages from control subjects but was undetectable in macrophages from patients with type 2 diabetes mellitus. In contrast, ABCA1 expression in macrophages was similar in both control subjects and patients with type 2 diabetes mellitus. Macrophage expression of ABCG1 in both patients and control subjects was induced by treatment with the liver X receptor agonist TO-901317. Upregulation of liver X receptor dramatically reduced foam cell formation in macrophages from patients with type 2 diabetes mellitus.Conclusions—ABCG1 expression and cholesterol efflux are reduced in patients with type 2 diabetes mellitus. This impaired ABCG1-mediated cholesterol efflux significantly correlates with increased intracellular cholesterol accumulation. Strategies to upregulate ABCG1 expression and function in type 2 diabetes mellitus could have therapeutic potential for limiting the accelerated vascular disease observed in patients with type 2 diabetes mellitus.


  • Sphingosine-1-Phosphate Induces an Antiinflammatory Phenotype in Macrophages

    by Jeniter E. Hughes, Suseela Srinivasan, Kevin R. Lynch, Richard L. Proia, Pawel Ferdek, Catherine C. Hedrick

    Activated macrophages acquire a proinflammatory (classic) or antiinflammatory (alternative) phenotype that influences atherosclerosis. The present study investigated whether sphingosine-1-phosphate (S1P), with its known antiinflammatory effects, could regulate the inflammatory phenotype of lipopolysaccharide (LPS)-stimulated mouse macrophages. Activation of macrophages by LPS significantly increases proinflammatory cytokine secretion. Pretreatment of macrophages with 500 nmol/L S1P markedly reduced LPS-mediated secretion of tumor necrosis factor-α, monocyte chemoattractant protein-1, and interleukin-12. Such antiinflammatory actions were also evident in LPS-stimulated macrophages treated with the S1P1 receptor–specific agonist SEW2871. Pharmacological antagonism of the S1P1 receptor on macrophages using the S1P1-specific antagonist VPC44116 also blocked proinflammatory cytokine secretion in response to LPS. Studies using bone marrow–derived macrophages from S1P2-deficient mice revealed that the S1P2 receptor did not play a pivotal role in this process. Thus, activation of the S1P1 receptor in mouse macrophages limits the expression of proinflammatory cytokines. Furthermore, we demonstrated that S1P increased arginase I activity and inhibited LPS-induced inducible NO synthase activity in LPS-treated macrophages, again through S1P1 receptor activation on macrophages. Analysis of a 1.7-kb region of the murine inducible NO synthase promoter revealed the presence of putative nuclear factor κB, activator protein-1, and STAT-1 response elements. Using inducible NO synthase promoter-reporter constructs, we found that S1P significantly reduced the nuclear factor κB–mediated induction of inducible NO synthase. These findings demonstrate an important role for S1P in the regulation of macrophage phenotypic switching. Therefore, we conclude that S1P promotes the production of an alternative antiinflammatory macrophage phenotype through activation of the macrophage S1P1 receptor.


  • Open Access

    Absence of the G Protein–Coupled Receptor G2A in Mice Promotes Monocyte/Endothelial Interactions in Aorta

    by David T. Bolick, Angela M. Whetzel, Marcus Skaflen, Tracy L. Deem, Jianyi Lee, Catherine C. Hedrick

    The G protein–coupled receptor G2A is highly expressed on macrophages and lymphocytes and has been localized to atherosclerotic plaques. We examined the role of G2A in modulating monocyte/endothelial interactions in the vessel wall. We measured adhesion of WEHI 78/24 monocytes to aortas of C57BL/6 (B6) and G2A-deficient (G2A −/− ) mice using an ex vivo adhesion assay. G2A −/− mice had 10-fold elevations in adhesion of monocytes to aortas. Injection of GFP-expressing wild-type macrophages into B6 and G2A −/− mice in vivo showed increased macrophage accumulation in the aortic wall of G2A −/− mice. We isolated aortic endothelial cells (ECs) from B6 and G2A −/− mice and found a 2-fold increase in intercellular adhesion molecule-1 and E-selectin surface expression on G2A −/− ECs using flow cytometry. Using ELISA, we found a 3-fold increase in interleukin-6 and monocyte chemoattractant protein-1 production by G2A −/− ECs compared with B6 ECs. We found a dramatic increase in nuclear localization of the p65 subunit of nuclear factor κB in G2A −/− ECs. Transfection of G2A into G2A −/− ECs to restore normal expression levels reduced p65 nuclear localization to 35%. Restoration of G2A expression in G2A −/− ECs significantly reduced intercellular adhesion molecule-1 and endothelial selectin surface expression and reduced monocyte chemoattractant protein-1 and interleukin-6 production. Restoring G2A to G2A −/− ECs reduced monocyte adhesion by 80% compared with G2A −/− ECs in a flow chamber assay. Absence of G2A in endothelium results in proinflammatory signaling and increased monocyte/endothelial interactions in the aortic wall. Thus, endothelial G2A expression may aid in prevention of vascular inflammation and atherosclerosis.


  • 12/15-Lipoxygenase Regulates Intercellular Adhesion Molecule-1 Expression and Monocyte Adhesion to Endothelium Through Activation of RhoA and Nuclear Factor-κB

    by David T. Bolick, A. Wayne Orr, Angela Whetzel, Suseela Srinivasan, Melissa E. Hatley, Martin A. Schwartz, Catherine C. Hedrick

    Background—12/15-lipoxygenase (12/15-LO) activity leads to the production of the proinflammatory eicosanoids 12-S-hydroxyeicosatetraenoic acid (12SHETE) and 13-S-hydroxyoctadecadienoic acid. We have previously shown a 3.5-fold increase in endothelial intercellular adhesion molecule (ICAM)-1 expression in mice overexpressing the 12/15-LO gene. We examined whether 12/15-LO activity regulated endothelial ICAM-1 expression.Methods and Results—Freshly isolated aortic endothelial cells (EC) from 12/15-LO transgenic mice had significantly greater nuclear factor-κB (NF-κB) activation and ICAM mRNA expression compared with C57BL/6J control. 12/15-LO transgenic EC showed elevated RhoA activity, and inhibition of RhoA using either C3 toxin or the Rho-kinase inhibitor Y-27632 blocked NF-κB activation, ICAM-1 induction, and monocyte adhesion. Furthermore, we show that 12SHETE activates protein kinase Cα, which forms a complex with active RhoA and is required for NF-κB–dependent ICAM expression in response to 12SHETE.Conclusions—The 12/15-LO pathway stimulates ICAM-1 expression through the RhoA/protein kinase Cα-dependent activation of NF-κB. These findings identify a major signaling pathway in EC through which 12/15-LO contributes to vascular inflammation and atherosclerosis.


  • Sphingosine-1-Phosphate Prevents Tumor Necrosis Factor-α–Mediated Monocyte Adhesion to Aortic Endothelium in Mice

    by David T. Bolick, Suseela Srinivasan, Kyu W. Kim, Melissa E. Hatley, Jeremy J. Clemens, Angela Whetzel, Nicole Ferger, Timothy L. Macdonald, Michael D. Davis, Philip S. Tsao, et al.

    Objective— Endothelial activation and monocyte adhesion to endothelium are key events in inflammation. Sphingosine-1-phosphate (S1P) is a sphingolipid that binds to G protein-coupled receptors on endothelial cells (ECs). We examined the role of S1P in modulating endothelial activation and monocyte–EC interactions in vivo. Methods and Results— We injected C57BL/6J mice intravenously with tumor necrosis factor (TNF)-α in the presence and absence of the S1P1 receptor agonist SEW2871 and examined monocyte adhesion. Aortas from TNF-α–injected mice had a 4-fold increase in the number of monocytes bound, whereas aortas from TNF-α plus SEW2871-treated mice had few monocytes bound ( P Conclusions— Thus, we provide the first evidence that S1P signaling through the endothelial S1P1 receptor protects the vasculature against TNF-α–mediated monocyte–EC interactions in vivo.


  • Open Access

    Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells

    by S. Srinivasan, M. E. Hatley, D. T. Bolick, L. A. Palmer, D. Edelstein, M. Brownlee, C. C. Hedrick

    Hyperglycaemia is a primary cause of vascular complications in diabetes. A hallmark of these vascular complications is endothelial cell dysfunction, which is partly due to the reduced production of nitric oxide. The aim of this study was to investigate the regulation of endothelial nitric oxide synthase (eNOS) activity by acute and chronic elevated glucose. Human aortic endothelial cells were cultured in 5.5 mmol/l (NG) or 25 mmol/l glucose (HG) for 4 h, 1 day, 3 days or 7 days. Mouse aortic endothelial cells were freshly isolated from C57BL/6J control and diabetic db/db mice. The expression and activity of eNOS were measured using quantitative PCR and nitrite measurements respectively. The binding of activator protein-1 (AP-1) to DNA in nuclear extracts was determined using electrophoretic mobility-shift assays. Acute exposure (4 h) of human aortic endothelial cells to 25 mmol/l glucose moderately increased eNOS activity and eNOS mRNA and protein expression. In contrast, chronic exposure to elevated glucose (25 mmol/l for 7 days) reduced total nitrite levels (46% reduction), levels of eNOS mRNA (46% reduction) and eNOS protein (65% reduction). In addition, AP-1 DNA binding activity was increased in chronic HG-cultured human aortic endothelial cells, and this effect was reduced by the specific inhibition of reactive oxygen species production through the mitochondrial electron transport chain. Mutation of AP-1 sites in the human eNOS promoter reversed the effects of HG. Compared with C57BL/6J control mice, eNOS mRNA levels in diabetic db/db mouse aortic endothelial cells were reduced by 60%. This decrease was reversed by the overexpression of manganese superoxide dismutase using an adenoviral construct. In diabetes, the expression and activity of eNOS is regulated through glucose-mediated mitochondrial production of reactive oxygen species and activation of the oxidative stress transcription factor AP-1.


  • Open Access

    12/15-Lipoxygenase Activity Mediates Inflammatory Monocyte/Endothelial Interactions and Atherosclerosis in Vivo

    by Kelly B. Reilly, Suseela Srinivasan, Melissa E. Hatley, Mary Kim Patricia, Joanne Lannigan, David T. Bolick, George Vandenhoff, Hong Pei, Rama Natarajan, Jerry L. Nadler, et al.


  • Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells

    by Mary Kim Patricia, Rama Natarajan, Alek N. Dooley, Felicia Hernandez, Jia-Li Gu, Judith A. Berliner, John J. Rossi, Jerry L. Nadler, Robert S. Meidell, Catherine C. Hedrick

    —The lipoxygenase (LO) pathway has been implicated as an important mediator of chronic glucose and platelet-derived growth factor (PDGF)-induced effects in the vascular system. Endothelial cells treated with 12LO products or cultured in high glucose showed enhanced monocyte adhesion, an important step in atherogenesis. We have previously reported that PDGF increased HETE levels in porcine aortic smooth muscle cells. Although several pharmacological inhibitors to the LO pathway are available, most lack specificity and may harbor undesirable side effects. Therefore, we developed a recombinant adenovirus expressing a hammerhead ribozyme (AdRZ) targeted against the porcine leukocyte-type 12LO mRNA to investigate the involvement of LO in glucose- and PDGF-mediated effects in vascular cells. Infection of porcine aortic endothelial cells with AdRZ reduced the level of glucose-enhanced 12LO mRNA expression as determined by quantitative, real-time reverse transcriptase–polymerase chain reaction. Reverse-phase HPLC and RIA analysis also revealed a corresponding decrease in glucose-stimulated 12HETE production in both the cellular and supernatant fractions. In the ribozyme-treated porcine aortic endothelial cells, there was marked inhibition of high glucose-stimulated monocyte adhesion. Infection with AdRZ also reduced PDGF-induced porcine aortic smooth muscle cell migration by approximately 50%. These studies demonstrate the efficacy of recombinant adenovirus expressing 12LO ribozyme in studying the effects of 12LO in vascular wall cells. They document an important role for the 12LO pathway in regulating inflammatory changes in endothelial cells and smooth muscle cells.